aTyr Pharma announces first major review article for Efzofitimod

aTyr Pharma announced the publication of a review article, titled, "Efzofitimod: a novel anti-inflammatory agent for sarcoidosis," in the peer-reviewed journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases. In the paper, the authors, led by Robert P. Baughman, M.D., Professor of Medicine at the University of Cincinnati Medical Center, describe the mechanism for efzofitimod as it relates to the granulomatous inflammation central to the pathophysiology of sarcoidosis, including the role of its binding partner neuropilin-2, a cell surface receptor that is highly expressed in sarcoid granulomas. "This first-ever review recognizes the potential of efzofitimod to be a transformative therapy for patients with pulmonary sarcoidosis," said Sanjay Shukla, M.D., M.S., President and CEO of aTyr. "EFZO-FIT is the first Phase 3 interventional study to be conducted in pulmonary sarcoidosis and is currently enrolling patients at multiple centers in the U.S, Europe and Japan. We believe this study presents a landmark opportunity to generate the most comprehensive investigational dataset for a treatment for sarcoidosis and represents a historic step forward in the attempt to develop a new treatment for patients with this disease."